肺力咳合剂联合信必可治疗咳嗽变异性哮喘临床研究

Clinical Study on Feilike Mixture Combined with Symbicort Inhaler for Cough Variant Asthma

目的:观察肺力咳合剂联合信必可治疗咳嗽变异性哮喘的临床效果。方法:将84例咳嗽变异性哮喘患者,按随机数字表法分为2组各42例。对照组采用信必可治疗,观察组采用肺力咳合剂联合信必可治疗。对比2组治疗前后咳嗽症状评分、气道炎症水平、肺功能情况以及治疗后不良反应。结果:2组治疗前白天、夜间咳嗽症状评分比较,差异无统计学意义(P>0.05)。治疗后,观察组白天、夜间咳嗽评分均较对照组降低,差异有统计学意义(P<0.05)。2组治疗前肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)、白细胞介素-4(IL-4)、IL-5及嗜酸性粒细胞(EOS)百分比水平比较,差异无统计学意义(P>0.05)。治疗后,观察组TNF-α、hs-CRP、IL-4、IL-5及EOS水平均较对照组降低,差异有统计学意义(P<0.05)。2组治疗前1s用力呼气容积(FEV1)、1s用力呼气容积/用力肺活量(FEV1/FVC)和呼气流量峰值占预计值百分比(PEFpred%)比较,差异无统计学意义(P>0.05)。治疗后,观察组FEV1、FEV1/FVC、PEFpred%较对照组升高,差异有统计学意义(P<0.05)。对照组不良反应发生率9.52%,观察组为7.14%,2组比较,差异无统计学意义(P>0.05)。结论:肺力咳合剂联合信必可治疗咳嗽变异性哮喘的临床效果显著,不仅可有效缓解咳嗽症状,减轻气道炎症水平,还可提高患者肺功能,不良反应少,安全可靠。

Objective : To observe the clinical effect of Feilike Mixture combined with Symbicort inhaler in treating cough variant asthma. Methods : A total of 84 patients with cough variant asthma were divided into two groups according to the random number table method, 42 cases in each group. The control group was treated with Symbicort inhaler, while the observation group was treated with Feilike Mixture combined with Symbicort inhaler. Symptom scores of cough, levels of airway inflammation, the lung function and adverse reactions after treatment were compared between the two groups. Results : There was no significant difference between the two groups in the comparison of the symptom scores of cough during daytime and night-time( P > 0. 05). After treatment, symptom scores of cough during daytime and night-time in the observation group were lower than those in the control group, the difference being statistically significant( P < 0. 05). There was no significant difference in the comparisons of tumor necrosis factor-α( TNF-α), hypersensitive C-reactive protein( hs-CRP), interleukin-4( IL-4), interleukin-5( IL-5) and the percentage of eosinophilic granulocytes( EOS) between the two groups before treatment( P > 0. 05). After treatment, the levels of TNF-α, hs-CRP, IL-4, IL-5 and EOS in the observation group were lower than those in the control group, the difference being statistically significant( P < 0. 05). There was no statistically significant difference in the comparisons of the forced expiratory volume( FEV1), the proportion of FEV1 to forced expiratory volume( FEV1/FVC) and the peak expiratory flow( PEF pred %) in the two groups before treatment( P > 0. 05). After treatment, FEV1, FEV1/FVC and PEF pred % were increased in the observation group when compared with those in the control group, the difference being statistically significant( P < 0. 05). The incidence of adverse reactions was 9. 52 % in the control group and 7. 14 % in the observation group, the difference between the two groups being not significant( P > 0. 05). Conclusion : The therapy of Feilike Mixture combined with Symbicort inhaler has significant therapeutic effect in treating cough variant asthma, which can not only effectively relieve cough symptoms and reduce airway inflammation of patients,but also improve their lung function.